Completed PHASE2/PHASE3 INTERVENTIONAL NCT00219635

Assessment Of Efficacy and Safety UK-390,957 In Men With Premature Ejaculation

A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled, Flexible Dose Study To Assess The Efficacy and Safety Of Oral UK-390,957 In Men With Premature Ejaculation

Sponsor: Pfizer

Conditions Ejaculation

Interventions UK-390,957

Updated 5 times since 2017 Last updated: Nov 5, 2012 Started: Jan 31, 2005 Primary completion: Jul 31, 2005 Completion: Jul 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00219635, this PHASE2/PHASE3 trial focuses on Ejaculation and remains completed. Sponsored by Pfizer, it has been updated 5 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Jan 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barrie, Canada , Beachwood, United States , Birmingham, United States , Dallas, United States , Devon, United Kingdom , Houston, United States , Kansas City, United States , Knoxville, United States , London, Canada , Malvern, Australia and 12 more locations